SCHEMBL7918480

SCHEMBL7918480

O=C(O)c1ccc2cccc(-c3cccc(O)c3F)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2D Q9UNK4 1/20 0.51
TTR P02766 3/20 0.44
HSD17B14 Q9BPX1 6/20 0.44
PTPN1 P18031 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA6 P23280 2/20 0.43
CA9 Q16790 2/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
PTPN11 Q06124 1/20 0.42
MCL1 Q07820 1/20 0.41
ACMSD Q8TDX5 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GRIN2D O15399 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2C Q14957 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7915823 0.88 PLA2G2D (0.50) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL7917788 0.86 PLA2G2D (0.52) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL7915369 0.85 PLA2G2D (0.46) PLA2G2DTTRHSD17B14PTPN1CA12
SCHEMBL16502418 0.84 TTR (0.48) PLA2G2DTTRHSD17B14PTPN1CA12
SCHEMBL7919877 0.84 PLA2G2D (0.50) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL7921957 0.84 PLA2G2D (0.50) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL16502442 0.83 PLA2G2D (0.52) PLA2G2DTTRPTPN1ACMSDMEN1
SCHEMBL16502582 0.82 GRIN2D (0.54) PLA2G2DTTRPTPN1MCL1ACMSD
SCHEMBL30304410 0.82 GRIN2D (0.58) PLA2G2DTTRPTPN1CA12CA1
SCHEMBL689384 0.82 GRIN2D (0.58) PLA2G2DTTRPTPN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
EP-2394987-A1 ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-14 EP disclosed
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A PLA2G2D 841/4885TTR 2550/4885HSD17B14 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.